Auro Laboratories Reports Strong Financial Performance in Q4 2023

Feb 06 2024 07:45 PM IST
share
Share Via
Auro Laboratories, a microcap pharmaceutical company, has reported a positive financial performance in the quarter ending December 2023. The company's net sales, operating profit, and profitability have all shown an upward trend, indicating strong financials. Auro Laboratories is poised for continued growth in the pharmaceutical industry.
Auro Laboratories, a microcap pharmaceutical company, has recently announced its financial results for the quarter ending December 2023. The company's stock has been given a 'Hold' call by MarketsMOJO.

According to the financial report, Auro Laboratories has shown positive performance in the quarter, with a score of 18, compared to 22 in the previous quarter. This indicates a slight decrease, but the company's overall financials are still strong.

One of the key factors contributing to Auro Laboratories' positive performance is its net sales, which have reached a high of Rs 17.98 crore in the last five quarters. This is a 36.4% increase from the average net sales of the previous four quarters, showing a positive trend in the company's sales.

The company's operating profit (PBDIT) has also seen a significant increase, reaching a high of Rs 4.08 crore in the last five quarters. This indicates a positive trend in the company's profitability.

Auro Laboratories has also shown improvement in its operating profit margin, reaching a high of 22.69% in the last five quarters. This indicates an increase in the company's efficiency.

The company's profit before tax (PBT) has also seen a positive trend, reaching a high of Rs 3.37 crore in the last five quarters. This indicates a strong financial performance by Auro Laboratories.

In terms of profitability, Auro Laboratories has shown a positive trend in its profit after tax (PAT), reaching a high of Rs 2.73 crore in the last five quarters. This shows that the company has been able to create higher earnings for its shareholders.

Overall, Auro Laboratories has shown a strong financial performance in the quarter ending December 2023. With positive trends in key financial indicators, the company is on track for continued growth and success in the pharmaceutical industry.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News